8.05
price up icon7.76%   0.58
pre-market  Pre-mercato:  8.06   0.010   +0.12%
loading
Precedente Chiudi:
$7.47
Aprire:
$7.61
Volume 24 ore:
4.73M
Relative Volume:
1.77
Capitalizzazione di mercato:
$585.35M
Reddito:
$409.00K
Utile/perdita netta:
$-101.35M
Rapporto P/E:
-4.9387
EPS:
-1.63
Flusso di cassa netto:
$-71.49M
1 W Prestazione:
-15.44%
1M Prestazione:
+17.01%
6M Prestazione:
+0.12%
1 anno Prestazione:
+206.08%
Intervallo 1D:
Value
$7.519
$8.4201
Intervallo di 1 settimana:
Value
$6.945
$9.70
Portata 52W:
Value
$2.4821
$14.84

Altimmune Inc Stock (ALT) Company Profile

Name
Nome
Altimmune Inc
Name
Telefono
(240) 654-1450
Name
Indirizzo
910 CLOPPER ROAD, GAITHERSBURG, MD
Name
Dipendente
59
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-05
Name
Ultimi documenti SEC
Name
ALT's Discussions on Twitter

Confronta ALT con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
ALT 8.05 585.35M 409.00K -101.35M -71.49M -1.63
VRTX 451.23 115.74B 10.63B -479.80M -1.35B 13.33
REGN 743.35 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 591.82 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 248.79 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 102.14 24.49B 3.30B -501.07M 1.03B 11.54

Altimmune Inc Stock (ALT) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-04-29 Downgrade Guggenheim Buy → Neutral
2024-01-24 Iniziato Goldman Neutral
2023-03-22 Downgrade Goldman Buy → Neutral
2022-12-01 Iniziato Goldman Buy
2021-12-29 Ripresa Jefferies Buy
2021-06-02 Iniziato H.C. Wainwright Buy
2021-02-11 Iniziato Guggenheim Buy
2020-12-14 Iniziato Jefferies Buy
2020-11-12 Reiterato B. Riley Securities Buy
2020-09-25 Iniziato B. Riley FBR Buy
2020-08-14 Iniziato Evercore ISI Outperform
2020-07-31 Iniziato Piper Sandler Overweight
2020-07-28 Iniziato JMP Securities Mkt Outperform
2020-02-24 Ripresa ROTH Capital Buy
2019-07-19 Iniziato ROTH Capital Buy
2017-10-09 Iniziato Piper Jaffray Overweight
Mostra tutto

Altimmune Inc Borsa (ALT) Ultime notizie

pulisher
Nov 18, 2024

FY2024 EPS Estimates for Altimmune Reduced by HC Wainwright - MarketBeat

Nov 18, 2024
pulisher
Nov 18, 2024

Altimmune, Inc. (NASDAQ:ALT) Receives $20.00 Consensus Target Price from Analysts - MarketBeat

Nov 18, 2024
pulisher
Nov 16, 2024

(ALT) Trading Report - Stock Traders Daily

Nov 16, 2024
pulisher
Nov 16, 2024

Altimmune, Inc. Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease at The Liver Meeting 2024 - Marketscreener.com

Nov 16, 2024
pulisher
Nov 15, 2024

Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024 - The Manila Times

Nov 15, 2024
pulisher
Nov 15, 2024

Altimmune's Pemvidutide Shows 68.5% Liver Fat Reduction in Phase 1b Trial Results | ALT Stock News - StockTitan

Nov 15, 2024
pulisher
Nov 15, 2024

What is B. Riley's Forecast for Altimmune FY2024 Earnings? - MarketBeat

Nov 15, 2024
pulisher
Nov 14, 2024

AMERIPRISE FINANCIAL INC's Strategic Acquisition in Altimmune Inc - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

B. Riley Weighs in on Altimmune's Q1 Earnings (NASDAQ:ALT) - MarketBeat

Nov 14, 2024
pulisher
Nov 14, 2024

Altimmune (NASDAQ:ALT) Given Buy Rating at HC Wainwright - MarketBeat

Nov 14, 2024
pulisher
Nov 14, 2024

Altimmune Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 14, 2024
pulisher
Nov 13, 2024

Altimmune: Pemvidutide As MASH Drug Could Provide Competitive Edge (NASDAQ:ALT) - Seeking Alpha

Nov 13, 2024
pulisher
Nov 13, 2024

Altimmune Unusual Options Activity For November 13 - Benzinga

Nov 13, 2024
pulisher
Nov 13, 2024

Altimmune’s Pemvidutide Gains Momentum: Sizeable TAMs In Obesity And Liver Health (ALT) - Seeking Alpha

Nov 13, 2024
pulisher
Nov 13, 2024

Altimmune provided key pipeline updates with Q3 report, says B. Riley - TipRanks

Nov 13, 2024
pulisher
Nov 13, 2024

Altimmune, Inc. (NASDAQ:ALT) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 13, 2024
pulisher
Nov 13, 2024

UBS Initiates Coverage of Altimmune (ALT) with Buy Recommendation - Nasdaq

Nov 13, 2024
pulisher
Nov 13, 2024

GSA Capital Partners LLP Sells 148,530 Shares of Altimmune, Inc. (NASDAQ:ALT) - MarketBeat

Nov 13, 2024
pulisher
Nov 13, 2024

Earnings call: Altimmune reports progress on pemvidutide trials, financials - Investing.com India

Nov 13, 2024
pulisher
Nov 13, 2024

Earnings call: Altimmune reports progress on pemvidutide trials, financials By Investing.com - Investing.com Canada

Nov 13, 2024
pulisher
Nov 13, 2024

Altimmune Inc (ALT) Q3 2024 Earnings Call Highlights: Strategic FDA Alignment and Expanding R&D Investments - GuruFocus.com

Nov 13, 2024
pulisher
Nov 13, 2024

Altimmune Inc (ALT) Q3 2024 Earnings Call Highlights: Strategic FDA Alignment and Expanding ... - Yahoo Finance

Nov 13, 2024
pulisher
Nov 13, 2024

Altimmune (ALT) Stock Soars 27%: Phase 2 Data On Obesity Drug Ignites Market Optimism - Barchart

Nov 13, 2024
pulisher
Nov 12, 2024

Altimmune Reports Q3 2024 Financial Results and Advances Drug Pipeline - TipRanks

Nov 12, 2024
pulisher
Nov 12, 2024

Altimmune Stock Rallies 30% on Updates - citybiz

Nov 12, 2024
pulisher
Nov 12, 2024

Altimmune stock rallies 30% on business updates, UBS buy rating - MSN

Nov 12, 2024
pulisher
Nov 12, 2024

Altimmune stock rallies 30% on business updates, UBS buy rating (NASDAQ:ALT) - Seeking Alpha

Nov 12, 2024
pulisher
Nov 12, 2024

Altimmune, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 12, 2024
pulisher
Nov 12, 2024

Traders Purchase Large Volume of Altimmune Call Options (NASDAQ:ALT) - MarketBeat

Nov 12, 2024
pulisher
Nov 12, 2024

Altimmune Inc Reports Q3 2024 Results: GAAP EPS of -$0.32 Beats Estimates, Revenue at $5,000 - GuruFocus.com

Nov 12, 2024
pulisher
Nov 12, 2024

Altimmune Appoints Gregory Weaver as CFO for Growth - TipRanks

Nov 12, 2024
pulisher
Nov 12, 2024

UBS Group Initiates Coverage on Altimmune (NASDAQ:ALT) - MarketBeat

Nov 12, 2024
pulisher
Nov 12, 2024

Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update - Yahoo Finance

Nov 12, 2024
pulisher
Nov 11, 2024

Altimmune Appoints Greg Weaver as CFO - citybiz

Nov 11, 2024
pulisher
Nov 11, 2024

Altimmune Appoints Chief Financial Officer - Contract Pharma

Nov 11, 2024
pulisher
Nov 11, 2024

Altimmune says ‘something raised attention of FDA’ - TipRanks

Nov 11, 2024
pulisher
Nov 11, 2024

Altimmune appoints Greg Weaver as CFO - TipRanks

Nov 11, 2024
pulisher
Nov 11, 2024

Altimmune Names Greg Weaver Chief Financial Officer - MarketWatch

Nov 11, 2024
pulisher
Nov 11, 2024

S&P 500 Index (INX) QuotePress Release - The Globe and Mail

Nov 11, 2024
pulisher
Nov 11, 2024

Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Nov 11, 2024
pulisher
Nov 11, 2024

Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer - The Manila Times

Nov 11, 2024
pulisher
Nov 11, 2024

TSX Communication Services Capped Index (TTTS) QuotePress Release - The Globe and Mail

Nov 11, 2024
pulisher
Nov 11, 2024

Altimmune, Inc. Appoints Greg Weaver as Chief Financial Officer - Marketscreener.com

Nov 11, 2024
pulisher
Nov 08, 2024

How Altimmune Could Grab a Big Chunk of the GLP-1 Market - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

Eli Lilly and Company (LLY-N) QuotePress Release - The Globe and Mail

Nov 08, 2024
pulisher
Nov 08, 2024

Institutional investors control 59% of Altimmune, Inc. (NASDAQ:ALT) and were rewarded last week after stock increased 11% - Simply Wall St

Nov 08, 2024
pulisher
Nov 08, 2024

Altimmune advances obesity treatment into Phase 3 trials By Investing.com - Investing.com South Africa

Nov 08, 2024
pulisher
Nov 07, 2024

Altimmune, FDA agree on efficacy measures for phase 3 trial of pemvidutide - Seeking Alpha

Nov 07, 2024
pulisher
Nov 07, 2024

Altimmune advances obesity treatment into Phase 3 trials - Investing.com India

Nov 07, 2024
pulisher
Nov 07, 2024

Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of Obesity - The Manila Times

Nov 07, 2024
pulisher
Nov 07, 2024

Altimmune Advances Obesity Drug: FDA Greenlights Major Phase 3 Program Design | ALT Stock News - StockTitan

Nov 07, 2024

Altimmune Inc Azioni (ALT) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$71.05
price up icon 0.69%
$18.62
price down icon 6.90%
$36.94
price down icon 0.94%
$364.33
price up icon 1.00%
$194.26
price up icon 3.46%
$102.14
price down icon 4.00%
Capitalizzazione:     |  Volume (24 ore):